Amedeo Smart

Free Medical Literature Service


 

Amedeo

Neonatology

  Free Subscription

Articles published in
Eur Respir J
    August 2022
  1. BIRKET SE
    A step forward for an intermediate cystic fibrosis population.
    Eur Respir J. 2022;60.
    >> Share

  2. NGUYEN-KHOA T, Hatton A, Drummond D, Aoust L, et al
    Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    Eur Respir J. 2022;60.
    >> Share

  3. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    >> Share

  4. MUILWIJK D, de Poel E, van Mourik P, Suen SWF, et al
    Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
    Eur Respir J. 2022;60.
    >> Share

    July 2022
  5. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    >> Share

  6. CHASSAGNON G, Campredon A, Vakalopoulou M, Burgel PR, et al
    Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
    Eur Respir J. 2022;60.
    >> Share

  7. ZHANG B, Zhang S
    Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Eur Respir J. 2022;60.
    >> Share

    May 2022
  8. RIGAUTS C, Aizawa J, Taylor SL, Rogers GB, et al
    R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.
    Eur Respir J. 2022;59.
    >> Share

    March 2022
  9. ZANNIN E, Rigotti C, Neumann RP, Dellaca RL, et al
    Oscillatory mechanics at 36 weeks post-menstrual age as markers of lung disease in preterm infants: a cohort study.
    Eur Respir J. 2022 Mar 2. pii: 13993003.03023-2021.
    >> Share

  10. KURZ JM, Ramsey KA, Rodriguez R, Spycher B, et al
    Association of lung clearance index with survival in individuals with cystic fibrosis.
    Eur Respir J. 2022;59.
    >> Share

    February 2022
  11. YEH HI, Hwang TC
    In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.
    Eur Respir J. 2022;59.
    >> Share

  12. HIRANI D, Alvira CM, Danopoulos S, Milla C, et al
    Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia.
    Eur Respir J. 2022;59.
    >> Share

  13. GOSS CH, Fajac I, Jain R, Seibold W, et al
    Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Eur Respir J. 2022;59.
    >> Share

  14. MORRISON CB, Shaffer KM, Araba KC, Markovetz MR, et al
    Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Eur Respir J. 2022;59.
    >> Share

    December 2021
  15. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    >> Share

  16. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    >> Share

  17. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    >> Share

  18. REEVES SR
    Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Eur Respir J. 2021;58.
    >> Share

  19. SETTE G, Lo Cicero S, Blacona G, Pierandrei S, et al
    Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
    Eur Respir J. 2021;58.
    >> Share

    November 2021
  20. BINGLE CD, Bingle L
    SPLUNC1 comes of age? Predicting acute exacerbations in cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

  21. KHANAL S, Webster M, Niu N, Zielonka J, et al
    SPLUNC1: a novel marker of cystic fibrosis exacerbations.
    Eur Respir J. 2021;58.
    >> Share

    October 2021
  22. SATRELL E, Clemm H, Roksund O, Hufthammer KO, et al
    Development of lung diffusion to adulthood following extremely preterm birth.
    Eur Respir J. 2021 Oct 8. pii: 13993003.04103-2020.
    >> Share

    September 2021
  23. HART K, Cousins M, Watkins WJ, Kotecha SJ, et al
    Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.
    Eur Respir J. 2021 Sep 29. pii: 13993003.01766-2021.
    >> Share

  24. MARTIN C, Burgel PR
    Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries.
    Eur Respir J. 2021;58.
    >> Share

  25. MCKONE EF, Ariti C, Jackson A, Zolin A, et al
    Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
    Eur Respir J. 2021;58.
    >> Share

    August 2021
  26. ANTIGNY F, Le Ribeuz H, Humbert M, Montani D, et al
    Comment on: Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype.
    Eur Respir J. 2021;58.
    >> Share

  27. FILIPOW N, Davies G, Main E, Sebire NJ, et al
    Unsupervised phenotypic clustering for determining clinical status in children with cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

    July 2021
  28. WECKMANN M, Bahmer T, Bulow Sand JM, Rank Ronnow S, et al
    COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
    Eur Respir J. 2021 Jul 29. pii: 13993003.03969-2020.
    >> Share

  29. DELACOURT C, Bertille N, Salomon LJ, Rashenas M, et al
    Predicting the risk of respiratory distress in newborns with congenital pulmonary malformations.
    Eur Respir J. 2021 Jul 15. pii: 13993003.00949-2021.
    >> Share

  30. MESSIKA J, Bunel V, Weisenburger G, Godet C, et al
    Pseudomonas aeruginosa eradication after lung transplantation: is it the tip of the iceberg?
    Eur Respir J. 2021;58.
    >> Share

  31. STAHL M
    Sensitive markers to detect progression of lung disease in children with cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

  32. STANOJEVIC S, Davis SD, Perrem L, Shaw M, et al
    Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

  33. FRAUCHIGER BS, Binggeli S, Yammine S, Spycher B, et al
    Longitudinal course of clinical lung clearance index in children with cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

    June 2021
  34. CORIATI A, Sykes J, Lemonnier L, Ma X, et al
    The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00014-2021.
    >> Share

  35. VANHAVERBEKE K, Slaats M, Al-Nejar M, Everaars N, et al
    Functional respiratory imaging provides novel insights into the long-term respiratory sequelae of bronchopulmonary dysplasia.
    Eur Respir J. 2021;57.
    >> Share

  36. HAGNER M, Albrecht M, Guerra M, Braubach P, et al
    IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease.
    Eur Respir J. 2021;57.
    >> Share

  37. LASELVA O, Bartlett C, Gunawardena TNA, Ouyang H, et al
    Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
    Eur Respir J. 2021;57.
    >> Share

  38. GILLAN JL, Davidson DJ, Gray RD
    Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.
    Eur Respir J. 2021;57.
    >> Share

    May 2021
  39. STEWART S, Chan YK, Playford D, Strange GA, et al
    Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography.
    Eur Respir J. 2021 May 28. pii: 13993003.00832-2021.
    >> Share

  40. HUGHES DA, Bokobza I, Carr SB
    Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis.
    Eur Respir J. 2021;57.
    >> Share

    April 2021
  41. COSIN-TOMAS M, Bustamante M, Sunyer J
    Epigenetic association studies at birth and the origin of lung function development.
    Eur Respir J. 2021;57.
    >> Share

  42. MUNIDASA S, Couch MJ, Rayment JH, Voskrebenzev A, et al
    Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis.
    Eur Respir J. 2021;57.
    >> Share

  43. DECLERCQ M, de Zeeuw P, Conchinha NV, Geldhof V, et al
    Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype.
    Eur Respir J. 2021;57.
    >> Share

  44. BARTELL JA, Sommer LM, Marvig RL, Skov M, et al
    Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.
    Eur Respir J. 2021;57.
    >> Share

    March 2021
  45. AGUSTI A, Breyer-Kohansal R, Faner R
    Transitioning from infancy to adulthood: a black box full of opportunities.
    Eur Respir J. 2021;57.
    >> Share

    February 2021
  46. O'SHEA KM, O'Carroll OM, Carroll C, Grogan B, et al
    Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
    Eur Respir J. 2021;57.
    >> Share

    January 2021
  47. HARDISTY GR, Law SM, Carter S, Grogan B, et al
    Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations.
    Eur Respir J. 2021;57.
    >> Share

  48. RAMALHO AS, Furstova E, Vonk AM, Ferrante M, et al
    Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
    Eur Respir J. 2021;57.
    >> Share

  49. BENGTSON CD, Kim MD, Anabtawi A, He J, et al
    Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance.
    Eur Respir J. 2021;57.
    >> Share

    November 2020
  50. MUKHERJEE N, Arathimos R, Chen S, Kheirkhah Rahimabad P, et al
    DNA methylation at birth is associated with lung function development till age 26 years.
    Eur Respir J. 2020 Nov 19. pii: 13993003.03505-2020.
    >> Share

    September 2020
  51. MARTIN C, Burgel PR
    Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?
    Eur Respir J. 2020;56.
    >> Share

    May 2020
  52. ERICSSON AC
    Bronchopulmonary dysplasia: a crime of opportunity?
    Eur Respir J. 2020;55.
    >> Share

  53. RANG C, Keating D, Wilson J, Kotsimbos T, et al
    Re-imagining cystic fibrosis care: next generation thinking.
    Eur Respir J. 2020;55.
    >> Share

  54. TURKOVIC L, Caudri D, Rosenow T, Breuer O, et al
    Structural determinants of long-term functional outcomes in young children with cystic fibrosis.
    Eur Respir J. 2020;55.
    >> Share

    April 2020
  55. POLLAK M, Shaw M, Wilson D, Grasemann H, et al
    Bronchodilator Responsiveness in Children with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis.
    Eur Respir J. 2020 Apr 8. pii: 13993003.00175-2020.
    >> Share

  56. KENTGENS AC, Oppelaar M, Merkus P
    A new breeze from an inspiring past: normality with multiple breath washout in school-aged children.
    Eur Respir J. 2020;55.
    >> Share

  57. FLUME PA, VanDevanter DR
    Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes.
    Eur Respir J. 2020;55.
    >> Share

    November 2018
  58. SKOPELJA-GARDNER S, Theprungsirikul J, Meagher RE, Beliveau CM, et al
    Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response.
    Eur Respir J. 2018 Nov 1. pii: 13993003.01891-2018.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016